Alumis Stock
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Sign up today and learn more about Alumis Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Alumis Stock
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Funding History
| May 2021 | $70.0M |
|---|---|
| January 2022 | $200M |
Management
Board of Directors
Alan Colowick
Board Member
Michael Rome
Chief Development Officer
Mark Bradley
Founder, President & CEO
June Lee
Board Member
Jim Tananbaum
Board Observer
Vikram Bajaj
Head of Research
Ken A Brameld
Vice President, Clinical Operations
Jeff Douglas
Senior Vice President, Chief Information Officer
David Zhang
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
